Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBOTT, KODYE LEE | 1 | 52.4% | +62.5% |
| XIE, XIAOZHEN | 1 | 55.9% | +65.9% |
| SCHUBERG, LAURA J | 1 | 23.7% | +36.7% |
| RAO, PADMAJA S | 1 | 69.5% | +35.9% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18078924 | DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY | SCHUBERG, LAURA J | 73d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18078924 | DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY | SCHUBERG, LAURA J | 73d overdue |
| 18019052 | CST6, CELLS EXPRESSING CST6 AND METHODS OF USE | XIE, XIAOZHEN | 26d overdue |
| 17799638 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | RAO, PADMAJA S | 12d |
| 17769663 | BIOLOGICALLY SYNTHESIZED HYDROXYAPATITE FOR BONE REGENERATION AND TISSUE ENGINEERING | NGUYEN, NGHI V | 28d |
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1674 | 1 |
| 1631 | 1 |
| 1627 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | 1634 | §112 | Final Rejection | — | Pending | Nov 20, 2024 |
| 18019052 | CST6, CELLS EXPRESSING CST6 AND METHODS OF USE | XIE, XIAOZHEN | 1674 | §103 | Non-Final OA | 26d overdue | Pending | Jan 31, 2023 |
| 18078924 | DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY | SCHUBERG, LAURA J | 1631 | Other | Non-Final OA | 73d overdue | Pending | Dec 10, 2022 |
| 17799638 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | RAO, PADMAJA S | 1627 | §103 | Non-Final OA | 12d | Pending | Aug 12, 2022 |
| 17769663 | BIOLOGICALLY SYNTHESIZED HYDROXYAPATITE FOR BONE REGENERATION AND TISSUE ENGINEERING | NGUYEN, NGHI V | 1653 | §112 | Non-Final OA | 28d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial